20/20 Biolabs, Inc. (AIDX) Stock

Healthcare · Medical Devices · Member of Other US Stocks

20/20 Biolabs, Inc. (AIDX) closed at USD 0.31 on 2026-10-14, a change of -98.7 % over the past year, with a market capitalization of USD 3.51M.

20/20 Biolabs, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

20/20 Biolabs, Inc. key figures

Previous close

USD 0.31 (2026-10-14)

1-year change

-98.7 %

Market cap

USD 3.51M

Enterprise value

USD 1.08M

P/E ratio (trailing)

-0.47

P/E ratio (forward)

n/a

EPS (trailing)

-0.58

EPS (forward)

n/a

PEG ratio

n/a

Price to book

2.08

Revenue growth

36.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.81

Employees

4

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About 20/20 Biolabs, Inc.

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for 20/20 Biolabs, Inc. and compare it with other stocks.